20,660 Shares in Athira Pharma, Inc. (NASDAQ:ATHA) Bought by Mirador Capital Partners LP

Mirador Capital Partners LP acquired a new stake in shares of Athira Pharma, Inc. (NASDAQ:ATHA) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 20,660 shares of the company’s stock, valued at approximately $57,000. Mirador Capital Partners LP owned approximately 0.05% of Athira Pharma as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Private Advisor Group LLC acquired a new position in shares of Athira Pharma during the 4th quarter worth about $32,000. Forefront Analytics LLC raised its holdings in shares of Athira Pharma by 43.0% during the fourth quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after acquiring an additional 8,955 shares during the last quarter. Clarius Group LLC lifted its position in shares of Athira Pharma by 35.8% in the fourth quarter. Clarius Group LLC now owns 53,551 shares of the company’s stock valued at $130,000 after acquiring an additional 14,124 shares in the last quarter. Laird Norton Trust Company LLC boosted its stake in shares of Athira Pharma by 21.3% in the third quarter. Laird Norton Trust Company LLC now owns 178,709 shares of the company’s stock worth $361,000 after acquiring an additional 31,400 shares during the last quarter. Finally, Perceptive Advisors LLC increased its position in shares of Athira Pharma by 12.6% during the fourth quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company’s stock worth $13,129,000 after purchasing an additional 605,686 shares in the last quarter. Institutional investors and hedge funds own 57.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $19.00 target price on shares of Athira Pharma in a research note on Thursday, June 20th.

Insider Buying and Selling at Athira Pharma

In other news, Director Kelly A. Romano purchased 15,000 shares of the stock in a transaction dated Friday, June 21st. The shares were purchased at an average price of $2.26 per share, with a total value of $33,900.00. Following the transaction, the director now owns 53,315 shares in the company, valued at approximately $120,491.90. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Athira Pharma news, Director Kelly A. Romano bought 27,400 shares of the business’s stock in a transaction on Monday, June 24th. The stock was bought at an average price of $2.42 per share, with a total value of $66,308.00. Following the completion of the purchase, the director now directly owns 80,715 shares in the company, valued at $195,330.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kelly A. Romano purchased 15,000 shares of the firm’s stock in a transaction dated Friday, June 21st. The stock was acquired at an average cost of $2.26 per share, for a total transaction of $33,900.00. Following the purchase, the director now owns 53,315 shares in the company, valued at $120,491.90. The disclosure for this purchase can be found here. 19.80% of the stock is owned by company insiders.

Athira Pharma Trading Down 5.3 %

ATHA opened at $2.51 on Tuesday. The firm has a market capitalization of $96.21 million, a PE ratio of -0.82 and a beta of 2.91. Athira Pharma, Inc. has a twelve month low of $1.33 and a twelve month high of $4.30. The firm’s 50-day moving average price is $2.38 and its 200 day moving average price is $2.72.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.11. As a group, analysts predict that Athira Pharma, Inc. will post -2.79 earnings per share for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.